<div id="readability-page-1"><div>Overview<ul><li>French-American spine surgery firm's 2025 sales rose 67% yr/yr to €9.2 mln</li><li>Signed two major partnerships for KEOPS-4ME platform in 2025</li></ul>Outlook<ul><li>Company expects sustained growth in U.S. market in 2026</li><li>SMAIO aims to finalize additional partnerships for K-Rods in 2026</li></ul>Result Drivers<ul><li>U.S. SALES GROWTH - U.S. sales rose by 138% to €7 mln, driven by adoption of the Kheiron system for complex spine surgeries</li><li>NEW PARTNERSHIPS - Two major partnerships for KEOPS-4ME platform signed</li><li>PROCEDURE INCREASE - Kheiron system procedures in U.S. rose to 326 from 180, supporting premium pricing</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>FY Sales</td></tr><tr><td>Beat/Miss</td><td>Miss</td></tr><tr><td>Actual</td><td>EUR 9.20 mln</td></tr><tr><td>Consensus Estimate</td><td>EUR 9.95 mln (2 Analysts)</td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;strong buy&#34; and the breakdown of recommendations is 2 &#34;strong buy&#34; or &#34;buy&#34;, no &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the pharmaceuticals peer group is &#34;buy.&#34;</li><li>Wall Street's median 12-month price target for SMAIO SA is €8.10, about 10.2% above its January 19 closing price of €7.35</li><li>The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 83 three months ago</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

French-American spine surgery firm SMAIO reported a 67% increase in 2025 sales, reaching €9.2 million. The company signed two major partnerships for its KEOPS-4ME platform and expects continued growth in the U.S. market in 2026, with U.S. sales rising 138% to €7 million. The average analyst rating is "strong buy," with a 12-month price target of €8.10, reflecting a positive outlook despite missing consensus estimates of €9.95 million.

Reuters

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

MAIA Biotech

VG Health

Spine surgery firm SMAIO 2025 sales surge 67%